RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2024 financial results on Monday, February 24, 2025.

Strong Operating Cash Flow and Reduction in Debt; Positioned to Pivot to Growth in Back Half Exploring Strategic Options for Personal Care Category

HOUSTON, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Orion Group Holdings, Inc. (NYSE: ORN) (the “Company”, “Orion”), a leading specialty construction company, today announced new Marine and Concrete awards for a total value of approximately $211.7 million. These projects are expected to begin in 2025 with varying completion dates extending through 2026. These awards further reinforce Orion's position as a leader in specialized Marine and Concrete construction.

NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against MGP Ingredients, Inc. ("MGP Ingredients" or "the Company") (NASDAQ:MGPI) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired MGP Ingredients securities between May 3, 2023 and October 30, 2024, both dates inclusive (the "Class Period").

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today commented on recent updates by the NCCN on circulating tumor DNA (ctDNA) molecular residual disease (MRD) testing in the Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for colon cancer, rectal cancer, and merkel cell carcinoma (MCC). In its updated guidelines for colon cancer1 and for rectal cancer2, NCCN now includes ctDNA as a high risk factor for recurrence in.

NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").

First Jointly Developed AI Agent Helps Customers Maximize Cisco Investments and Boosts Productivity News Summary: Powerful Partnership: The first of several AI agents being developed by Cisco with Mistral AI as a strategic technology partner, to help drive Cisco's Customer Experience (CX) move towards an Agentic-AI-Led future. AI-Powered Efficiency: The AI Renewals Agent streamlines and enhances the creation process for Cisco's Renewals team by analyzing data from 50 sources to build custom proposals tied to customer outcomes.

MIAMI, FL / ACCESS Newswire / February 10, 2025 / The recent executive order banning paper straws in the United States marks a pivotal shift in sustainability policy. While well-intentioned, the push for alternatives like Paper Pulp and new chemistry for plastics has been proven problematic and with significant commercial challenges -prone to breaking down, leaving a poor user experience, and requiring resources that aren't always greener.

Boca Raton, Florida, Feb. 10, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”) , a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, announced today, following a Type C meeting with the U.S. Food and Drug Administration (FDA), its intent to submit a BLA in the US and Marketing Authorization Application (MAA) in the UK and EU supported by data from the MissionEB clinical trial investigating CORDStrom as a disease-modifying therapy for treating RDEB in pediatric patients.

NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Regeneron securities between November 2, 2023 and October 30, 2024, both dates inclusive (the "Class Period").

NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Micron Technology, Inc. ("Micron" or "the Company") (NASDAQ:MU) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Micron securities between September 28, 2023 and December 18, 2024, both dates inclusive (the "Class Period").

NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ:AZN) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired AstraZeneca securities between February 23, 2022 and December 17, 2024, both dates inclusive (the "Class Period").

NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Transocean Ltd. ("Transocean" or "the Company") (NYSE:RIG) and certain of its officers.

Move expected to broaden access to Ekso Bionics' portable exoskeleton device for individuals living with spinal cord injuries and other mobility challenges across the United States Move expected to broaden access to Ekso Bionics' portable exoskeleton device for individuals living with spinal cord injuries and other mobility challenges across the United States

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones.

PRINCETON, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, February 19, 2025, at 8:30 a.m. ET to discuss financial results for the full-year ended December 31, 2024.

PetMed Express stock could surge or sink after this week's quarterly earnings release, but don't read too much into this near-term event. A disappointing earnings release won't necessarily shatter the bull case, and could, in fact, push this stock back down to "back up the truck" price levels. Conversely, even if PETS rallies on strong results, this may not capture all of the potential long-term upside.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--Bristol Myers Squibb Announces Positive Topline Results for Breyanzi in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma.

Oil futures rose Monday, finding support after three straight weekly declines that took crude to its lows of the new year.

DALLAS--(BUSINESS WIRE)--AECOM, the trusted global infrastructure leader, today announced key leadership appointments to further strengthen its global operations and enhance client delivery. Bane Gaiser has been named Buildings + Places Global Business Line Chief Executive, Richard Whitehead as Europe & India Regional Chief Executive, and Sam Donelson as U.S. East & Latin America Regional Chief Executive. With extensive industry experience, including long-standing careers at AECOM, thes.